Onvansertib Ph 1b/2 mCRC Trial Data Update

Mark Erlander, Ph.D. Chief Executive Officer

20222021 2008 2013 2017

20222021 2008 2013 2017

• • •

1st LINE 2nd LINE

2nd LINE HISTORICAL ORR 5% 11.4% 13%

91.1%

Onvansertib DOWNSTREAM S G2 G1 M

Katherine Ruffner, MD Chief Medical Officer

WEEKS 1−2 WEEKS 3−4

WEEKS 1−2 WEEKS 3−4 1 2 3

WEEKS 1−2 WEEKS 3−4 HISTORICAL ORR* 5% 11.4% 13% HISTORICAL mPFS* 4.5−5.7 mo 20% ≥6 mo

Enrollment*

No major/unexpected toxicities GRADE TEAEs* 1 2 3 4 All • • • GRADE TEAEs* 1 2 3 4 All

Evaluable Patients Jan 2021 As of Sept 16 As of Dec 3 As of Jan 18 Sept 2021

Jan 2021 As of Sept 16 As of Dec 3 As of Jan 18 Sept 2021 Evaluable Patients • Webcast data release • –

Jan 2021 As of Sept 16 As of Dec 3 As of Jan 18 Sept 2021 Evaluable Patients 1 2 3 Clinical benefits observed

% c h a n g e in t a rg e t le si o ns f ro m b a se lin e

% c h a n g e in t a rg e t le si o n s fr o m b a se lin e % c h a n g e in t a rg e t le si o n s fr o m b a se lin e Patients achieving CR+PR Patients achieving SD

KRAS Variant CR+PR SD PD Total 6

20222021

Predictive response biomarker • • CR+PR SD PD -100 -50 0 %Change in KRAS MAF Mean CR+PR -96 SD -74 PD -63 ✱ ✱✱

• – – – • •

CLINICAL PROGRAMS OTHER COMBINATIONS • • •

Preclinical IND En. Ph 0/1 Ph 2 Status Partners

DNA DAMAGING AGENTS MICROTUBULE TARGETING EPIGENETICS

Learn more at www.CardiffOncology.com